期刊
VACCINE
卷 27, 期 1, 页码 2-9出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.10.028
关键词
Vaccines; Malaria; Sporozoite; History
资金
- NIH Institute of Allergy and Infectious Diseases [A163530]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI063530] Funding Source: NIH RePORTER
Advances towards protective vaccines against malaria were made feasible by the development of a rodent model of mammalian malaria that allowed production of all stages of the malaria parasite for Study. Investigations with sporozoites (the stage transmitted by mosquitoes in their saliva) demonstrated that immunization with radiation-attenuated sporozoites could produce a solid, sterile immunity, first shown in studies with mice and later with human volunteers. Protective immune mechanisms involve antisporozoite antibodies that immobilize sporozoites injected into the skin by mosquitoes, followed by CD4+ and CD8+ T-cells acting against liver stage parasites produced by sporozoites that have escaped antibody-based immunity and invaded hepatocytes. Two alternative approaches now being used in human trials are immunization with intact, attenuated sporozoites vs. immunization with sub-unit vaccines based on immunogenic components of sporozoites or liver stage parasites. in addition to immunization against these pre-erythrocytic stages, encouraging progress is being made on immunization against blood stage parasites and on immunization for production of transmission-blocking antibodies. There is reason to be optimistic that one or more of the approaches will work on a large scale, and that a multi-stage vaccine may be able to combine several of these approaches in a sequential immunological assault against the malaria parasite as it progresses through its stages. (c) 2008 Elsevier Ltd. All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据